Stryker Co. (NYSE:SYK) Shares Sold by Ensign Peak Advisors Inc

Ensign Peak Advisors Inc trimmed its position in shares of Stryker Co. (NYSE:SYK - Free Report) by 5.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 677,604 shares of the medical technology company's stock after selling 41,131 shares during the quarter. Ensign Peak Advisors Inc owned approximately 0.18% of Stryker worth $243,971,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Kohmann Bosshard Financial Services LLC acquired a new position in shares of Stryker in the 4th quarter valued at $25,000. Rakuten Securities Inc. lifted its stake in shares of Stryker by 618.2% in the 4th quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company's stock valued at $28,000 after purchasing an additional 68 shares during the period. Centricity Wealth Management LLC acquired a new position in shares of Stryker in the 4th quarter valued at $30,000. BankPlus Trust Department acquired a new position in shares of Stryker in the 4th quarter valued at $33,000. Finally, VSM Wealth Advisory LLC acquired a new position in shares of Stryker in the 4th quarter valued at $36,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker Trading Down 0.4%

Shares of SYK stock traded down $1.59 on Friday, hitting $380.87. 758,784 shares of the stock traded hands, compared to its average volume of 1,356,009. The firm's 50-day moving average price is $365.47 and its two-hundred day moving average price is $374.48. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. The stock has a market capitalization of $145.37 billion, a PE ratio of 49.08, a PEG ratio of 2.93 and a beta of 0.93. Stryker Co. has a twelve month low of $314.93 and a twelve month high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The medical technology company reported $2.84 EPS for the quarter, topping the consensus estimate of $2.73 by $0.11. The firm had revenue of $5.87 billion for the quarter, compared to analyst estimates of $5.68 billion. Stryker had a net margin of 13.25% and a return on equity of 23.58%. The business's revenue for the quarter was up 11.9% compared to the same quarter last year. During the same period in the prior year, the business posted $2.50 EPS. As a group, analysts anticipate that Stryker Co. will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Monday, June 30th will be issued a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a yield of 0.88%. The ex-dividend date is Monday, June 30th. Stryker's dividend payout ratio (DPR) is presently 45.41%.

Insider Transactions at Stryker

In other news, Director Ronda E. Stryker sold 200,000 shares of the firm's stock in a transaction that occurred on Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total value of $75,392,000.00. Following the completion of the sale, the director now directly owns 3,417,326 shares of the company's stock, valued at $1,288,195,208.96. This trade represents a 5.53% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Allan C. Golston sold 2,458 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the sale, the director now directly owns 14,895 shares of the company's stock, valued at $5,705,827.65. This represents a 14.16% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 5.90% of the company's stock.

Analysts Set New Price Targets

Several analysts have commented on SYK shares. StockNews.com lowered Stryker from a "buy" rating to a "hold" rating in a report on Thursday, March 6th. Barclays raised their price objective on Stryker from $418.00 to $443.00 and gave the company an "overweight" rating in a report on Monday, February 10th. Sanford C. Bernstein set a $450.00 price objective on Stryker in a report on Monday, May 5th. JPMorgan Chase & Co. raised their price objective on Stryker from $420.00 to $445.00 and gave the company an "overweight" rating in a report on Wednesday, January 29th. Finally, Citigroup restated a "buy" rating and set a $450.00 price target on shares of Stryker in a research report on Wednesday, February 26th. Five research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $427.05.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.